EVE Health Group Limited - Asset Resilience Ratio
EVE Health Group Limited (EVE) has an Asset Resilience Ratio of 22.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EVE Health Group Limited short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how EVE Health Group Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see EVE Health Group Limited balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down EVE Health Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EVE long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$929.66K | 22.86% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$929.66K | 22.86% |
Asset Resilience Insights
- Good Liquidity Position: EVE Health Group Limited maintains a healthy 22.86% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
EVE Health Group Limited Industry Peers by Asset Resilience Ratio
Compare EVE Health Group Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Nestle S.A.
SW:NESN |
Packaged Foods | 2.01% |
|
Uni-President Enterprises Corp
TW:1216 |
Packaged Foods | 4.53% |
|
The Magnum Ice Cream Company N.V.
AS:MICC |
Packaged Foods | 0.11% |
|
Conagra Brands, Inc.
NYSE:CAG |
Packaged Foods | 0.29% |
|
Alfa S.A.B. de C.V.
MX:ALFAA |
Packaged Foods | 0.74% |
|
Premium Brands Holdings Corporation
TO:PBH |
Packaged Foods | 0.49% |
|
Chongqing Fuling Zhacai Group Co Ltd
SHE:002507 |
Packaged Foods | 27.78% |
|
Juewei Food Co Ltd
SHG:603517 |
Packaged Foods | 3.18% |
Annual Asset Resilience Ratio for EVE Health Group Limited (2011–2025)
The table below shows the annual Asset Resilience Ratio data for EVE Health Group Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 21.90% | AU$903.42K ≈ $639.23K |
AU$4.12 Million ≈ $2.92 Million |
+17.69pp |
| 2024-06-30 | 4.21% | AU$106.17K ≈ $75.12K |
AU$2.52 Million ≈ $1.79 Million |
-9.45pp |
| 2022-06-30 | 13.66% | AU$1.10 Million ≈ $780.03K |
AU$8.07 Million ≈ $5.71 Million |
-12.85pp |
| 2021-06-30 | 26.50% | AU$3.16 Million ≈ $2.24 Million |
AU$11.92 Million ≈ $8.44 Million |
-9.90pp |
| 2020-06-30 | 36.41% | AU$5.14 Million ≈ $3.64 Million |
AU$14.11 Million ≈ $9.99 Million |
+31.24pp |
| 2019-06-30 | 5.17% | AU$453.78K ≈ $321.08K |
AU$8.78 Million ≈ $6.21 Million |
-49.98pp |
| 2018-06-30 | 55.15% | AU$4.11 Million ≈ $2.91 Million |
AU$7.46 Million ≈ $5.28 Million |
+42.33pp |
| 2017-06-30 | 12.82% | AU$393.62K ≈ $278.51K |
AU$3.07 Million ≈ $2.17 Million |
+1.66pp |
| 2015-06-30 | 11.16% | AU$309.52K ≈ $219.01K |
AU$2.77 Million ≈ $1.96 Million |
+7.00pp |
| 2014-06-30 | 4.16% | AU$340.95K ≈ $241.25K |
AU$8.19 Million ≈ $5.79 Million |
+0.22pp |
| 2013-06-30 | 3.94% | AU$325.50K ≈ $230.31K |
AU$8.26 Million ≈ $5.84 Million |
+0.47pp |
| 2012-06-30 | 3.48% | AU$823.02K ≈ $582.34K |
AU$23.68 Million ≈ $16.76 Million |
-21.68pp |
| 2011-06-30 | 25.16% | AU$6.71 Million ≈ $4.75 Million |
AU$26.68 Million ≈ $18.88 Million |
-- |
About EVE Health Group Limited
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erect… Read more